Document Detail

Hemorrhagic complications of thrombolytic therapy.
MedLine Citation:
PMID:  22452232     Owner:  NLM     Status:  In-Process    
Stroke is the most frequent neurological disorder, and the most common cause of severe disability compared to other diseases. Recombinant tissue plasminogen activator (rt-PA) is the only approved specific therapy for acute ischemic stroke. Hemorrhage is a significant complication of thrombolytic treatment. This study, which included a hundred patients (52 male and 48 female), was aimed at assessing the safety according to our experience with 100 thrombolytic treatments for stroke. The death rate related to hemorrhage after thrombolysis was 3%. The frequency of hemorrhagic events (hemorrhagic infarctions type 1 and 2, parenchymal hematomas type 1 and 2) was 16%. The study results have shown that the intravenous recombinant tissue plasminogen activator (rt-PA) therapy is safe.
Zoran Vujković; Dusko Racić; Sinisa Miljković; Vlado Dajić
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Medicinski pregled     Volume:  65     ISSN:  0025-8105     ISO Abbreviation:  Med. Pregl.     Publication Date:    2012 Jan-Feb
Date Detail:
Created Date:  2012-03-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  2985249R     Medline TA:  Med Pregl     Country:  Serbia    
Other Details:
Languages:  eng     Pagination:  9-12     Citation Subset:  IM    
Department of Neurology, Clinical Center Banjaluka, Bosnia and Herzegovina.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The role of cytological evaluation of pleural fluid in diagnosing malignant mesothelioma.
Next Document:  [Effect of a tight necktie on intraocular pressure].